Navigation Links
FDA Approves New Multiple Sclerosis Drug
Date:3/28/2013

THURSDAY, March 28 (HealthDay News) -- A new drug called Tecfidera has been approved to treat adults with relapsing forms of multiple sclerosis, the U.S. Food and Drug Administration said Wednesday.

The approval is based on the results of two clinical trials showing that patients who took Tecfidera (dimethyl fumarate) capsules had fewer MS relapses than those who took an inactive placebo. One of the trials also showed that a worsening of MS-related disability occurred less often in patients who took the drug than in those who took the placebo.

"Tecfidera will be a welcome addition to the growing list of agents that alter the course of multiple sclerosis," said one expert, Dr. Fred Lublin, director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York City.

"Based on the clinical trial data available, this new agent has very impressive efficacy data and a good safety profile," he added.

The FDA said that Tecfidera may lower levels of white blood cells, which help protect the body from infection. Lower levels of white blood cells may increase the risk of infection, but no significant increase in infections occurred in patients taking the drug.

Before starting treatment with Tecfidera, and each year after, doctors should check patients' white blood cell counts, the FDA advised.

Flushing (warmth and redness), nausea, vomiting and diarrhea were the most common side effects in patients taking the drug, especially at the start of treatment with Tecfidera, which is made by Biogen Idec in Massachusetts.

"No drug provides a cure for multiple sclerosis, so it is important to have a variety of treatment options available for patients," Dr. Russell Katz, director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"Multiple sclerosis can impair movement, sensation and thinking, and have a profound impact on a person's quality of life," he added.

MS is an autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body, resulting in problems such as muscle weakness and difficulty with coordination and balance.

For most MS patients, periods of worsening disability (relapses) are initially followed by recovery periods (remissions). Over time, these recovery periods may be incomplete, resulting in a progressive increase in disability.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.

-- Robert Preidt

SOURCES: Fred Lublin, M.D., director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York City; U.S. Food and Drug Administration, news release, March 27, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
8. FDA Approves New Once-a-Day HIV Pill
9. FDA Approves New Type of Flu Vaccine
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves 1st Skin Patch to Combat Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves New Multiple Sclerosis Drug
(Date:1/19/2017)... ... January 19, 2017 , ... For the ... Lawrenceville, New Jersey and the surrounding area, is inaugurating a charity event ... more commonly known as Lou Gehrig's disease or motor neurone disease, is a ...
(Date:1/19/2017)... Los Angeles, CA (PRWEB) , ... January 18, 2017 , ... ... serious hazards while driving during a rain storm by slowing down and increasing the ... published on Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... that will simplify the editing process for all media productions," said Christina Austin ... package of 30 simplistically styled self-animating paragraphs designed for multi-lined text purposes. ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting of a ... about the benefits of fidgeting to relieve stress and anxiety. No one was ... Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 on the ...
(Date:1/18/2017)... USA; SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... (PRWEB) January 18, 2017 -- Global public health organization NSF ... arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment ... water treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... CLEVELAND , Jan. 18, 2017  ViewRay, ... the world,s first and only clinical MRI-guided radiation ... gross proceeds of approximately $26.1 million through a ... Puissance Capital Management led the financing and was ... OrbiMed Advisors, LLC and Kearny Venture Partners, and ...
(Date:1/19/2017)... 18, 2017 The Academy of Managed ... Administration (FDA) for its release today of draft ... decision makers can proactively share clinical and economic ... as emerging therapies awaiting FDA approval. ... that AMCP developed during two multi-stakeholder meetings last ...
(Date:1/18/2017)... 2017 Research and Markets has announced the addition ... User - Global Opportunity Analysis and Industry Forecast, 2014-2022" report to ... Vital signs ... to reach $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring devices ...
Breaking Medicine Technology: